Datamonitor, Dec 2010, Pages: 21
information available
SWOT COMPANY PROFILE: Glazer's WholesaleDrug Company Inc.
Key Facts: Glazer's WholesaleDrug Company Inc.
Company Overview: Glazer's WholesaleDrug Company Inc.
Business Description
Pacific Bridge Medical, Jan 2010, Pages: 148
A. Governing Legislation
B. Agencies
V. Drug Registration and Import
A. Overview
B. New Drug Registration
C. Import Registration
D. Import License
E. Adverse Event Reporting
VI. Manufacturing
GBI Research, Feb 2010, Pages: 107
.1 GBI Research Report Guidance
3 Drug Discovery Process – Overview
3.1 Process of Early Preclinical Drug Discovery
3.1.1 Pre-discovery
3.1.2 Target Identification
3.1.3 Target Validation
3.1.4 Lead
Datamonitor, June 2011, Pages: 22
's WholesaleDrug Company Inc.'s business description, segment overview, company history, products and services, SWOT analysis, management statement, key executives and biographies, key competitors, locations
Pacific Bridge Medical, April 2011, Pages: 144
government guidelines regarding new drug manufacturing and sales in India.
- A new listing of Adverse Drug Reaction (ADR) Monitoring Centers in India. I: Overview of India’s Economy
II: Overview of India
Business Horizons, Jan 2010, Pages: 816
The most exhaustive and comprehensive book ever available on the subject.
- Safety and Toxicity in Herbal Drugs
- Ethnobotany in Drug Evaluation
- Macro-Morphographical Studies
- Development
Business Review, Sep 2010, Pages: 15
Synopsis
Business Review’s Glazer's WholesaleDrug Co., Inc. contains a company overview, key facts, locations and subsidiaries, news and events as well as a SWOT analysis of the company.
Summary
Yano Research Institute Ltd., Dec 2010, Pages: 187
.
- Key points are described succinctly for changing generic drug market environments and market player trends in Japan. CHAPTER 1: MARKET ENVIRONMENTS
Overview
Market Conditions in United States
Yano Research Institute Ltd., Dec 2010, Pages: 187
.
- Key points are described succinctly for changing generic drug market environments and market player trends in Japan. CHAPTER 1: MARKET ENVIRONMENTS
Overview
Market Conditions in United States
Takeda Pacific, Oct 2004, Pages: 123
of Nearing Patent Expirations
Late Stage Drug Pipeline in 2003
6.Navigating World Drug Regulatory Organizations Drug
R&D and Regulatory Approval Processes
Drug Approvals in the USA (North America)
Overview
Just Pharma Reports, Oct 2010, Pages: 60
Dialysis
3.2 Diagnosis Procedure Combinations
3.2.1 Coverage
3.2.2 Impact on Drug Use
3.2.3 High-cost Drug Exclusions
4. Pricing Down the Distribution Chain
4.1 Wholesaling
4.2 Paying Wholesalers
4
Decision Resources, Inc., Sep 2006, Pages: 30
?
Scope
Retiree benefits: overview of Medicare drug benefit program; the impact of increasing coinsurance for seniors in Japan; U.S. employers’ plan to restrict retirees’ health benefits.
Growth of generics
Global Industry Analysts, Inc., Aug 2011, Pages: 228
2. INDUSTRY OVERVIEW 5
Internet Globalizes Drug Sales through ePharmacies 5
Table 1: Global: Percentage Distribution of ePharmacies by
Host Country (2008) (includes corresponding Graph/Chart) 5
Decision Resources, Inc., June 2008, Pages: 66
, average wholesale prices in the United States again increased; conversely, the annual inflation rate for drug costs was at its lowest point in 30 years, one-quarter of what it was two years ago. What
PMR Ltd, March 2011, Pages: 161
of the top players in the market I. Report methodology
II. Executive summary
III. Overview of the pharmaceutical market in Poland
- Main trends and events on drug market
- Market introduction
PMR Ltd, March 2011, Pages: 161
of the top players in the market I. Report methodology
II. Executive summary
III. Overview of the pharmaceutical market in Poland
- Main trends and events on drug market
- Market introduction
Business Insights, July 2005
Lilly and Merck & Co.
Executive Summary
Overview of drug safety issues
Regulation of drug safety in the US and Europe
New legislation and regulation in the US and Europe
Industry initiatives
Digital Vector, Aug 2005, Pages: 360
or developing generic version of new drugs.
DISTRIBUTION
The Chinese pharmaceutical distribution sector is very fragmented with about 17,000 state-owned pharmaceutical wholesalers. Direct marketing to doctors
